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Background: Smoking prevalence, behaviours, physician counselling regarding smoking cessa-
tion, and smoking cessation medications were evaluated among male and female smokers with
COPD and asthma compared to the general smoking population.
Methods: Data from the large, nationally representative Canadian Community Health Survey
(CCHS) was used (for 2003 CCHS, n Z 134,072). All data were based on self-report, including
the presence of COPD and asthma which were defined by health-professional diagnosis. Nico-
tine addiction was assessed by the Fagerstrom Test for Nicotine Dependence.
Results: In 2003, 32.8% of individuals with COPD, 21.0% with asthma, and 22.1% without COPD
or asthma were current smokers. After adjusting for sociodemographic and smoking behaviour
confounders, among current smokers, greater odds of high or very high nicotine addiction were
observed among women with versus without COPD (OR Z 2.49, 95% CI Z 1.41e4.39), and
among women with versus without asthma (OR Z 1.74, 95% CI Z 1.01e2.99), but no associa-
tions were seen among men. Smokers with COPD and asthma were no more likely to have
received physician counselling regarding smoking cessation, nor smoking cessation pharmaco-
therapy compared to the general smoking population.
Conclusions: Gender differences were observed in the association between COPD and asthma
and higher nicotine addition levels in current smokers. These findings could in part explain
population trends showing that COPD and asthma are increasing more rapidly in women. Physi-
cian counselling and pharmacotherapy for smoking cessation do not appear to be received
more frequently among individuals with COPD or asthma compared to the general smoking po-
pulation, despite the greater vulnerability of such patients to smoking effects.
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ronto.ca (N.T. Vozoris), m.stanbrook@utoronto.ca (M.B. Stanbrook).
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Cigarette smoking among individuals with chronic obstruc-
tive pulmonary disease (COPD) or asthma is known to
increase respiratory symptoms,1,2 worsen lung function,3,4
and elevate exacerbation rates.5,6 In addition, smoking
confers a relative risk of mortality that is two times higher
in COPD compared to the risk associated with smoking in
other health conditions.7 Despite the significant adverse
health effects of smoking in COPD and asthma, precise
estimates of the prevalence of smoking in COPD or asthma
compared to that in the general smoking population and
analyses of key variables that may underlie this (such as
sociodemographic characteristics, smoking behaviours, and
use of physician counselling and smoking cessation phar-
macotherapy) are lacking. Understanding the scope and
nature of smoking behaviours and cessation strategies in
COPD and asthma might enable healthcare providers and
policymakers to target resources better and develop more
effective approaches to help smokers within these high-risk
disease groups to quit successfully. Although population
trends clearly show that smoking-related lung diseases like
COPD and asthma are on the rise in women,8,9 gender
effects on smoking behaviour and cessation among those
with respiratory diseases are poorly understood.
The objectives of this study were to compare smoking
among individuals with COPD or asthma to the general
smoking population, and to evaluate whether smoking
behaviours, physician counselling regarding smoking
cessation, and smoking cessation medication use differed
among smokers with COPD or asthma compared to the
general smoking population. Additionally, we sought to
determine gender influences on the interaction between
smoking and respiratory disease.
Methods
Data sources
This study was conducted with data from the Canadian
Community Health Survey (CCHS). The CCHS is an ongoing
survey undertaken by Statistics Canada that collects cross-
sectional self-reported sociodemographic and health data
on a nationally representative sample of the Canadian
population aged 12 years and older.10 A detailed description
of the survey design and methodology appears else-
where.10,11 Three cycles of the CCHS have been completed
thus far (2000e01, 2003, 2005), each with a sample of
w130,000 respondents ranging from ages 12e80 þ years.
We focused on the 2003 CCHS cycle because, unlike other
cycles of the CCHS, it included special smoking theme data.
The overall response rate for the 2003 CCHS was 80.7%,
yielding a total sample of 134,072 respondents.10
Variable definitions
Smoking status was based on self-report. Current smokers
were defined as respondents who smoked cigarettes either
daily or occasionally at the time of the survey. Former
smokers were defined as respondents who had smoked at
least 100 cigarettes in their lifetime but did not smoke dailyor occasionally at the time of the survey. Those respon-
dents who refused to state or did not know their current
smoking status were excluded from the analysis (0.4% of
2003 CCHS sample). Presence of COPD and asthma were
based on self-reported health-professional diagnosis of the
medical condition that had lasted, or was expected to last,
for 6 months or longer. Questions regarding diagnosis of
COPD were asked only of individuals’ ages 30 years and
older (w75% of 2003 CCHS sample). We categorized
respondents as having COPD if they reported affirmatively
to having either chronic bronchitis or emphysema or COPD,
and if they were aged 40 years or older. Those respondents
who refused to state or did not know their COPD and
asthma status were excluded from the analysis (w0.1% of
2003 CCHS sample).
All sociodemographic and smoking habit data were
based on self-report. The 2003 CCHS included special
smoking theme content. Questions on nicotine addiction
were based on the Fagerstrom Test for Nicotine Depen-
dence (FTND).12 The internal reliability, test-retest reli-
ability, and validity (by comparison with smoking
abstinence, other cigarette dependence scales, and body
cotinine levels) of the FTND have been confirmed in
a number of countries.13e15 An FTND score of 0e2 was
classed as very low, a score of 3e4 as low, a score of 5 as
medium, a score of 6e7 as high, and a score of 8e10 as very
high nicotine dependence.13 Questions on stage of smoking
cessation were based on the widely used Prochaska
model.16 Questions about physician counselling of smoking
cessation in the past year, including whether or not the
regular medical doctor advised the respondent to quit
smoking, and whether or not the doctor gave any specific
help/information to quit smoking, were asked. Questions
about smoking cessation medication use in the past year,
including nicotine patches, nicotine gum or nicotine candy,
and bupropion, were also asked. Response rates to the
questions on nicotine addiction, smoking stage of change,
physician counselling of smoking cessation, and smoking
cessation medications were very high, ranging from 86% to
94%, depending on the question.
Statistical analysis
All analyses were performed on SAS version 9.1.3. The
prevalences of current and former smoking among individ-
uals with asthma, COPD, and without COPD and asthma
were calculated for each of the three CCHS cycles. Using
the 2003 CCHS, associations between respiratory disease
status with sociodemographic and smoking behaviour
characteristics were analyzed using c2 tests for inter-group
proportion differences at the variable level.
Associations between respiratory disease status and
nicotine dependence, physician counselling regarding
smoking cessation, and smoking cessation medications were
analyzed using multiple logistic regression. Comparisons of
smokers with versus without COPD, smokers with versus
without asthma, and smokers with COPD versus smokers
with asthma were examined. Unadjusted odds were first
calculated. Two adjusted regression models were run for
nicotine dependence. The first model included all the
sociodemographic variables listed in Table 1. The second
model included all the variables contained in the first
Table 1 Sociodemographic characteristics of current smokers with COPD, asthma, and without COPD or asthma in Canada in
2003.








Male 54.9 41.3 39.0
Female 45.1 58.7 61.0
Province 0.0006
Atlantic Canada 8.1 9.2 9.2
Quebec 26.9 28.1 30.6
Ontario 37.4 38.1 38.5
Western Canada 27.1 24.3 21.5
Territories 0.4 NA NA
Agea <0.0001
<40 29.6 39.0 0
40e59 56.4 49.2 59.3
60e79 12.9 11.1 37.4
>80 1.1 NA 3.4
Marital status <0.0001
Married/common-law 67.6 63.2 54.4
Single/widowed/separated/divorced 32.4 36.8 45.6
Don’t know/not stated (n Z 77)
Children <12yrs in home <0.0001
Yes 26.6 30.8 8.4
No 73.4 69.2 91.6
Immigrant <0.0001
Yes 17.8 9.3 12.2
No 82.2 90.8 87.8
Don’t know/not stated (n Z 706)
Race <0.0001
Caucasian 88.4 92.6 94.5
Visible minority 11.2 7.4 5.5
Don’t know/not stated (n Z 733)
Education <0.0001
<Secondary 23.5 27.3 40.4
Secondary 22.4 23.4 17.0
Some post-secondary 6.9 7.3 4.6
Post-secondary 47.2 42.0 37.9
Don’t know/not stated (n Z 731)
Income source <0.0001
Employment 80.6 72.9 49.2
EI/workers’ comp/welfare 5.1 11.8 12.3
Senior’s benefits 12.0 12.4 33.5
Other 2.4 2.9 5.1
Don’t know/not stated (n Z 1400)
Income adequacy <0.0001
Lowest income 3.7 6.3 8.4
Lower middle 6.7 12.5 16.6
Middle 19.6 23.7 27.0
Upper middle 37.5 28.2 28.4
Highest income 32.5 29.3 19.7
Don’t know/not stated (n Z 2836)
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Has a regular medical doctor <0.0001
Yes 82.4 84.9 92.7
No 17.6 15.1 7.3
Don’t know/not stated (n Z 9)
Has insurance for prescription medications <0.0001
Yes 77.7 79.4 80.6
No 22.3 20.6 19.4
Don’t know/not stated (n Z 160)
NA - These estimates are not presented because according to Statistics Canada data release guidelines they are unreliable estimates for
making inference at the population level given that they are based on less than 30 respondents.
a Age was defined as a categorical variable in the public use microdata file of the CCHS, and not as a continuous variable.
b p-value reflects comparison among all three groups at the variable level.
Table 2 Smoking behaviour characteristics of current smokers with COPD, asthma, and without COPD or asthma in Canada
in 2003.







Type of Smoker <0.0001
Daily 81.9 81.4 90.6
Occasional 18.1 18.6 9.4
Total years smoking <0.0001
<10 3.7 3.5 NA
11e20 21.5 25.2 NA
21e30 35.2 35.5 21.8
31e40 24.1 22.6 34.7
41e50 10.5 8.5 23.6
>50 5.1 4.8 17.3
Packs per day smoking <0.0001
< ¼ pack 9.1 5.9 5.1
¼ pack e ½ pack 21.6 18.9 16.7
> ½ pack e 1 pack 42.5 44.9 38.8
> 1 pack e 2 packs 25.4 27.8 36.7
> 2 packs 1.5 NA NA
Attempted to stop smoking at least
once for at least 24 h during past year
0.003
Yes 47.8 55.9 47.6
No 52.2 44.2 52.4
Fagerstrom tolerance test <0.0001
Very low nicotine dependence 22.5 25.1 13.5
Low nicotine dependence 27.2 22.1 18.7
Medium nicotine dependence 14.3 11.3 14.4
High nicotine dependence 22.9 29.2 36.0
Very high nicotine dependence 10.2 12.4 17.3
Prochaska’s smoking stage of change 0.2
Pre-contemplation 38.4 37.1 43.5
Contemplation 42.0 41.2 39.6
Preparation 19.7 21.7 16.8
NA - These estimates are not presented because according to Statistics Canada data release guidelines they are unreliable estimates for
making inference at the population level given that they are based on less than 30 respondents.
a p-value reflects comparison among all three groups at the variable level.
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duration, and quantity, in order to assess whether any
observed relationships with nicotine addiction were inde-
pendent of these. One adjusted regression model was run
for the variables relating to physician counselling regarding
smoking cessation and smoking cessation medications that
included all the sociodemographic and the smoking char-
acteristics listed in Tables 1 and 2. We looked for the
presence of gender-respiratory disease interactions
relating to all the outcome variables by including an
interaction term in each regression equation. When this
interaction term was statistically significant, we reported
a stratified analysis by gender. This occurred only for the
nicotine dependence variable.
The CCHS uses a complex sampling design, employing
stratification and multi-stage clustering techniques, and
unequal probabilities of selecting survey respondents. To
account for the unequal probabilities of selecting respon-
dents, all results were weighted using the survey sample
weights provided. All sample weights were re-scaled prior
to each analysis by dividing the original weight by the
average weight of respondents included in the specific
analysis, according to Statistics Canada guidelines.10 To
account for the effects of stratification and clustering on
variance estimates, all confidence intervals were calcu-
lated using bootstrap resampling techniques with a set of
bootstrap weights created by Statistics Canada. Ethics
approval was granted by the University of Toronto Office of
Research Ethics.
Results
Of the 99,254 participants in the 2003 CCHS who were asked
and reported their respiratory disease and smoking status,
6062 (6.1%) self-reported asthma, 3453 (3.5%) COPD, and
90,010 (90.4%) neither asthma nor COPD. An estimated
32.8% of individuals with COPD, 21.0% with asthma, and
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Figure 1 Percent of current and former smokers among
individuals with COPD, asthma, and without COPD or asthma in
Canada between 2000 and 2005.Between the years 2000e2005, changes in the prevalence
of smoking fell similarly by 4e6% among individuals with
asthma and those without COPD or asthma. In contrast, the
prevalence of smoking among individuals with COPD has
consistently been about 1.5 times greater and increased by
3% between 2000e2005 (Fig. 1). Between the years
2000e2005, the prevalence of former smoking increased
more among individuals with asthma and without COPD or
asthma than among individuals with COPD (Fig. 1). The
overall prevalence of COPD and asthma did not change
between 2000e2005 (data not shown).
Compared to current smokers without COPD or asthma,
greater proportions of current smokers with asthma or
COPD were female, resided in eastern Canada, had poorer
socioeconomic status as reflected by education level, social
assistance receipt, and income level, had a regular medical
doctor, and had insurance for prescription medications
(Table 1). Fewer immigrants and more Caucasians who
smoked had asthma or COPD. Smokers with COPD tended to
be older and live in single-person households.
The greatest proportion of daily smoking was found
among individuals with COPD and the lowest proportion was
found among individuals with asthma (Table 2). Smokers
with COPD had been smoking the longest and the most
packs per day, and smokers with asthma the least.
Increased smoking duration in COPD was independent of
the respondent’s age (data not shown). Compared to
smokers without COPD or asthma, similar proportions of
smokers with COPD and greater proportions of smokers with
asthma had made attempts to quit smoking. Higher levels
of nicotine dependence were also seen among smokers with
asthma or COPD, but Prochaska stages of change were not
different among the three groups.
In unadjusted analyses, both male smokers and female
smokers with COPD had significantly greater odds of
reporting high or very high nicotine addiction compared to
their respective non-disease counterparts (Table 3). After
adjusting for sociodemographic confounders, both associa-
tions remained statistically significant. After additionally
adjusting for smoking pattern, duration, and quantity, the
association with higher nicotine addiction remained signifi-
cant only for female smokers with COPD. In unadjusted
analyses, female smokers with asthma had significantly
greater odds of reporting high or very high nicotine addiction
compared to their respective non-disease counterparts, and
the statistical significance of this association remained even
after controlling for sociodemographic and smoking behav-
iour confounders. No significant differences in high or very
high nicotine addiction were found between male smokers
with versus without asthma, or between smokers with COPD
versus smokers with asthma of either gender.
Smokers with COPD did not differ from smokers without
COPD for any of the physician counselling or smoking
cessation medication variables. In unadjusted analyses,
compared to smokers without asthma, smokers with asthma
had significantly greater odds of reporting receipt of nico-
tine patches and their doctors advising them to quit
smoking. However, in adjusted analsyes, the association
with use of nicotine patches was no longer significant, but
the odds of using nicotine gum or nicotine candy was now
significantly greater among smokers with asthma. None of
the physician counselling or smoking cessation medication
Table 3 Odds of reporting high or very high nicotine addiction among smokers with COPD, asthma, and without COPD or
asthma in Canada in 2003.
n/N Crude OR (95% CI) Adjusted OR
(95%CI) Model 1a
Adjusted OR
(95% CI) Model 2b
All subjects
Smokers with COPD vs.
smokers without COPD
208/451 vs. 2245/6820 2.26 (1.63e3.12) 2.43 (1.75e3.83) 2.14 (1.41e3.25)
Smokers with asthma vs.
smokers without asthma
285/634 vs. 2168/6637 1.61 (1.18e2.17) 1.57 (1.16e2.10) 1.53 (1.05e2.22)
Smokers with COPD vs.
smokers with asthma
110/262c vs. 285/634 1.37 (0.82e2.28) 1.43 (0.84e2.45) 1.26 (0.67e2.40)
Men only
Smokers with COPD vs.
smokers without COPD
76/158 vs. 1213/3378 2.00 (1.12e3.56) 2.00 (1.11e3.57) 1.73 (0.95e3.13)
Smokers with asthma vs.
smokers without asthma
109/239 vs. 1180/3297 1.34 (0.81e2.21) 1.27 (0.77e2.08) 1.24 (0.75e2.04)
Smokers with COPD vs.
smokers with asthma
44/94c vs. 109/239 1.29 (0.56e2.98) 1.20 (0.44e3.31) 1.43 (0.41e4.96)
Women only
Smokers with COPD vs.
smokers without COPD
132/293 vs. 1032/3442 2.48 (1.66e3.70) 2.49 (1.41e4.39) 2.49 (1.41e4.39)
Smokers with asthma vs.
smokers without asthma
176/395 vs. 988/3340 1.85 (1.29e2.67) 1.74 (1.01e2.99) 1.74 (1.01e2.99)
Smokers with COPD vs.
smokers with asthma
66/168c vs. 176/395 1.39 (0.75e2.58) 1.30 (0.58e2.92) 1.30 (0.58e2.92)
a Model 1 adjusted for all the sociodemographic variables listed in Table 1.
b Model 2 adjusted for all the sociodemographic variables listed in Table 1, as well as type of smoker (i.e., daily versus occasional),
total years smoked, and packs per day smoked.
c Total numbers of individuals with COPD in this third comparison does not equal the respective number presented in the first
comparison due to overlap of respondents between asthma and COPD categories.
Table 4 Odds of reporting various smoking cessation strategies among smokers with COPD, asthma, and without COPD or
asthma in Canada in 2003.
Smoking cessation variable n/N Crude OR (95%CI) Adjusted ORa
(95% CI)
In past 12 months, regular medical doctor advised respondent to quit smoking
Smokers with COPD vs. smokers without COPD 122/164 vs. 1560/2396 1.68 (0.88e3.21) 1.92 (0.97e3.98)
Smokers with asthma vs. smokers without asthma 167/223 vs. 1515/2337 2.22 (1.35e3.65) 2.22 (1.35e3.65)
Smokers with COPD vs. smokers with asthma 82/112b vs. 167/223 0.55 (0.24e1.27) 0.56 (0.17e1.89)
In past 12 months, regular medical doctor gave specific help/information to quit smoking
Smokers with COPD vs. smokers without COPD 74/163 vs. 861/2386 1.36 (0.76e2.43) 1.58 (0.87e2.89)
Smokers with asthma vs. smokers without asthma 103/223 vs. 832/2326 1.03 (0.65e1.62) 1.06 (0.64e1.77)
Smokers with COPD vs. smokers with asthma 49/111b vs. 103/223 1.51 (0.72e3.17) 1.46 (0.59e3.63)
In past 12 months, tried nicotine patch to quit smoking
Smokers with COPD vs. smokers without COPD 132/320 vs. 1664/5015 1.42 (1.00e2.03) 1.38 (0.94e2.02)
Smokers with asthma vs. smokers without asthma 191/469 vs. 1605/4866 1.47 (1.06e2.04) 1.39 (1.00e1.91)
Smokers with COPD vs. smokers with asthma 74/192b vs. 191/469 0.81 (0.46e1.43) 0.86 (0.41e1.79)
In past 12 months, tried nicotine gum or nicotine candy to quit smoking
Smokers with COPD vs. smokers without COPD 61/320 vs. 794/5013 1.44 (0.90e2.31) 1.44 (0.89e2.34)
Smokers with asthma vs. smokers without asthma 89/468 vs. 766/4865 1.46 (0.99e2.16) 1.59 (1.08e2.32)
Smokers with COPD vs. smokers with asthma 36/192b vs. 89/468 0.78 (0.38e1.59) 0.63 (0.27e1.49)
In past 12 months, tried bupropion to quit smoking
Smokers with COPD vs. smokers without COPD 62/320 vs. 679/5012 1.40 (0.81e2.42) 1.23 (0.71e2.14)
Smokers with asthma vs. smokers without asthma 78/468 vs. 663/4864 1.13 (0.75e1.70) 1.16 (0.77e1.74)
Smokers with COPD vs. smokers with asthma 39/192b vs. 78/468 1.29 (0.64e2.59) 1.10 (0.48e2.54)
a Adjusted for all the sociodemographic variables listed in Table 1 and all the smoking characteristics listed in Table 2.
b Total numbers of individuals with COPD in this third comparison does not equal the respective number presented in the first
comparison due to overlap of respondents between asthma and COPD categories.
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Smoking and COPD or asthma 483variables were observed to differ between smokers with
COPD and smokers with asthma (Table 4).Discussion
The prevalence of smoking in COPD remains substantially
higher than in the general smoking population, while the
prevalence of smoking in asthma is similar to population
levels. Our observation that more women with COPD or
asthma smoke, and that such women have higher nicotine
addiction levels, may in part explain why the prevalence of
COPD and asthma is increasing more among women than
men. Greater nicotine addiction may in part explain the high
prevalence of continued smoking among individuals with
COPD. In contrast, reduced desire to quit smoking and fewer
attempts at quitting smoking do not appear to explain the
higher prevalence of continued smoking in COPD. These
findings suggest that more physician counselling regarding
smoking cessation, coupled with more aggressive prescrip-
tion and increased access to smoking cessation medications,
is needed for smokers with COPD and asthma in order to
improve cessation rates in these vulnerable populations.
Recentpopulationstudies fromtheUS17e19 andEurope20e22
have similarly found high rates of current smoking among
individuals with COPD in the 30e40% range, while the prev-
alence of smoking in asthma was lower but still significant in
the 20e30% range and comparable to that of the general
smoking population. In contrast to previous studies,17,19,21,22
we found a significantly greater proportion of women among
smokers with asthma, and particularly COPD, compared to
the general smoking population. This discrepancy may be
explained by the fact that previous reports were based data
from selected populations outside of Canada,17,19,21,22
whereas our study was based on nationally representative
data from Canada. The finding of more women among
smokers with COPD or asthma is important because women
smokers with COPD reported 2.5 times greater odds, and
women smokers with asthma 1.7 times greater odds, of high
or very high nicotine addiction compared to their non-
disease smoking counterparts, which could in part explain
population trends showing that COPD and asthma are
increasing more rapidly in women.8,9
As in previous studies,17,19,22,23 we found lower indices
of socioeconomic status among smokers with asthma, and
particularly COPD, compared to the general smoking pop-
ulation. Given the significantly higher rates of low income
and social assistance receipt among smokers with COPD or
asthma, the affordability of smoking cessation aids for
individuals with COPD or asthma will likely be more prob-
lematic than for the general smoking population.
Similar to previous studies,20,22 we have found increased
nicotine dependence among smokers with COPD. However,
our observations of an association between high nicotine
addiction and COPD or asthma specifically among women
smokers, and that these associations are independent of
smoking pattern, duration, and quantity, represent unique
and novel contributions of our study. In the general smoking
population, mixed results have been reported regarding
gender differences with respect to nicotine addiction.24,25
Similar to other studies,22,26 reduced desire to quit
smoking and fewer attempts at quitting smoking were notseen among smokers with COPD or asthma. Similar to Yun
et al.,19 we did not find significantly increased odds of
physician counselling regarding smoking cessation among
smokers with COPD or asthma. We also report no increased
use nicotine patches and buproprion among these groups.
Although we did not observe gender differences among
smokers with COPD or asthma with respect to physician
counselling of smoking cessation and smoking cessation
medications, in the general smoking population women have
been reported to receive smoking cessation counselling and
bupropion, but not nicotine replacement, with increased
frequency compared to men.27
Strengths of this study are that it is based on a very
large, nationally representative sample of the Canadian
population including data on a wide range of sociodemo-
graphic, smoking behaviour, and smoking cessation vari-
ables. Upwards of 16 sociodemographic and smoking
behaviour variables were included in our logistic regression
models to control for potential confounding. Our study also
has several limitations. There may be underestimation of
certain variables (e.g. nicotine addiction) and over-
estimation of others (e.g. smoking stage of change) due to
inaccurate reporting for reasons of social desirability. The
data is also based entirely on self-report, thereby poten-
tially introducing recall bias. Although respondents were
asked to report health-professional diagnosed conditions,
there is likely to be some degree of disease misclassifica-
tion among the COPD, asthma, and no COPD or asthma
groups. However, CCHS self-report of health-professional
diagnosis for several diseases, including for asthma, has
been found to have fair to good agreement with population-
based health administrative disease case ascertainment.28
Some respondents indicated receiving a diagnosis of both
asthma and COPD, accounting for 37% of the COPD group
and 17% of the asthma group. This limited our ability to
observe differences between the asthma and COPD groups,
but makes analyses where differences were observed with
COPD more conservative. Although participants’ response
rates to questions on nicotine addiction, smoking stage of
change, and smoking cessation strategies were very high,
because these questions were included in the survey for
only selected health regions (17%e32% of the total health
regions in Canada, depending on the question), results may
not be generalizable to all of Canada.
Further research is needed to confirm and better under-
stand the gender influence on the association between
nicotine addiction and smoking in COPD and asthma. Current
approaches to smoking cessation may need to be specifically
adapted for women smokers with COPD or asthma given the
higher degree of nicotine addiction they display. Although
individuals with COPD or asthma are at increased risk
compared to the general smoking population for poorer
health outcomes if they continue to smoke, rates of physician
counselling and smoking cessation medication use were
surprisingly not found to be any higher in these vulnerable
groups. The affordability of smoking cessation medications
for individuals with COPD or asthma may be one of the
barriers to their usage given the higher rates of low socio-
economic status observed in these groups. More counselling
and prescription of smoking cessation aids by physicians,
along with increased patient access to such medications, for
example through government funding, might facilitate
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